丁苯酞对帕金森病患者临床症状的影响

目的 探讨丁苯酞(NBP)对改善帕金森病(PD)患者运动和非运动症状的疗效情况。 方法 选择2014年9月—2016年12月期间蚌埠医学院第一附属医院收治的帕金森病患者103例,采用随机数字表法分为NBP组(43例)和对照组(60例)。所有患者继续其最初的药物治疗方案,NBP组患者给予NBP每次200 mg,每天3次,口服24周。对比2组治疗前及治疗第12、24、48周的震颤评分和运动迟缓加强直评分,MoCA评分以及不良事件(AEs)。 结果 2组组内治疗前后运动迟缓加强直评分、震颤评分和MoCA评分比较差异有统计学意义(均P<0.05);2组治疗前运动迟缓加强直评分、震颤评分评分和MoCA评分差异均无统计学意义(均P>0.05),但治疗第12周、24周和48周,NBP组运动迟缓加强直评分(26.26±13.57、21.72±11.71、20.52±11.77)显著低于对照组评分(33.03±18.24、30.55±18.02、26.78±16.57);震颤评分(31.42±22.66、27.23±18.15、25.33±18.18)也显著低于对照组评分(47.43±28.88、41.08±28.07、37.55±28.61);而NBP组MoCA评分(20.37±3.45、25.03±3.26、28.36±3.38)显著高于对照组MoCA评分(18.98±3.22、20.03±3.51、24.43±3.34),均P<0.05。NBP相关的不良事件不常见。 结论 丁苯酞可安全有效地改善帕金森病患者的运动和非运动症状。 

Effect of butylphthalide on the clinical symptoms of patients with Parkinson's disease

Objective To investigate the efficacy of butylphthalide(NBP) in improving the motor and non-motor symptoms of patients with Parkinson's disease(PD). Methods A total of 103 PD patients admitted to the First Affiliated Hospital of Bengbu Medical College from September 2014 to December 2016 were selected and randomly assigned to NBP treatment group(43 cases) and control group(60 cases). All patients continued their initial prescribed drug regimen, with NBP administered at 200 mg per dose, 3 times per day, orally, for 24 weeks in the NBP group. Tremor score, motor retardation enhancement direct score, MoCA score, and adverse events(AEs) were compared between the two groups before treatment and at 12, 24, and 48 weeks of treatment. Results There were statistically significant differences between the two groups in motor retardation enhancement direct score, tremor score and MoCA score before and after treatment(all P<0.05). There was no statistical significance in the enhancement of motor retardation direct score, tremor score and MoCA score before treatment in the two groups(all P>0.05). At 12, 24 and 48 weeks, the enhancement of motor retardation direct score in the NBP group(26.26±13.57, 21.72±11.71, 20.52±11.77) were significantly lower than that in the control group(33.03±18.24, 30.55±18.02, 26.78±16.57), and the score of tremor(31.42±22.66, 27.23±18.15, 25.33±18.18) were also significantly lower than that of control group(47.43±28.88, 41.08±28.07, 37.55±28.61). The MoCA score of the NBP group(20.37±3.45, 25.03±3.26, 28.36±3.38) were significantly higher than that of the control group(18.98±3.22, 20.03±3.51, 24.43±3.34), all P<0.05. NBP-related adverse events were uncommon. Conclusion Butylphthalide can improve the motor and non-motor symptoms of PD patients safely and effectively.